EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors

Enora Dolivet iD, Léopold Gaichies, Corinne Jeanne, Céline Bazille, Mélanie Briand, Mégane Vernon, Florence Giffard, Frédéric Leprêtre, Laurent Poulain, Christophe Denoyelle iD, Nicolas Vigneron, Raffaèle Fauvet iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242116016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Enora Dolivet und 11 weiteren Autor:innen. Beteiligte Einrichtung: ANTICIPE UMR (1086) (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine in Ovarian Carcin…. Hauptthemen laut MEDLINE: MicroRNAs, Ovarian Neoplasms, Neoplasms, Cystic, Mucinous, and Serous, Adenocarcinoma, Mucinous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ligue Contre le Cancer, Les Courants de la Liberté, Cancéropole Nord-Ouest.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial ovarian cancers (EOCs) are a heterogeneous collection of malignancies, each with their own developmental origin, clinical behavior and molecular profile. With less than 5% of EOC cases, mucinous ovarian carcinoma is a rare form with a poor prognosis and a 5-year survival of 11% for advanced stages (III/IV). At the early stages, these malignant forms are clinically difficult to distinguish from borderline (15%) and benign (80%) forms with a better prognosis due to the large size and heterogeneity of mucinous tumors. Improving their diagnosis is therefore a challenge with regard to the risk of under-treating a malignant form or of unnecessarily undertaking radical surgical excision. The involvement of microRNAs (miRNAs) in tumor progression and their potential as biomarkers of diagnosis are becoming increasingly recognized. In this study, the comparison of miRNA microarray expression profiles between malignant and borderline tumor FFPE samples identified 10 down-regulated and 5 up-regulated malignant miRNAs, which were validated by individual RT-qPCR. To overcome normalization issues and to improve the accuracy of the results, a ratio analysis combining paired up-regulated and down-regulated miRNAs was performed. Although 21/50 miRNA expression ratios were significantly different between malignant and borderline tumor samples, any ratio could perfectly discriminate the two groups. However, a combination of 14 pairs of miRNA ratios (double ratio) showed high discriminatory potential, with 100% of accuracy in distinguishing malignant and borderline ovarian tumors, which suggests that miRNAs may hold significant clinical potential as a diagnostic tool. In summary, these ratio miRNA-based signatures may help to improve the precision of histological diagnosis, likely to provide a preoperative diagnosis in order to adapt surgical procedures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsOvarian NeoplasmsNeoplasms, Cystic, Mucinous, and SerousAdenocarcinoma, MucinousPrecancerous ConditionsFemaleHumansCarcinoma, Ovarian EpithelialBiomarkers, Tumor

Stichwörter der Autor:innen

cancer diagnosismicroRNAmucinous borderline ovarian tumormucinous ovarian cancerovarian carcinomaratio

Substanzen

MicroRNAsBiomarkers, Tumor

Autor:innen und Institutionen

  • ANTICIPE UMR (1086) (Interdisciplinary Research Unit for Cancers Prevention and Treatment), BioTICLA Laboratory (Precision Medicine in Ovarian Carcinoma), Federative Structure 4207 Normandie Oncologie, Université de Cae…
  • Unicancer, Comprehensive Cancer Center F. Baclesse, 3 Avenue Général Harris, F-14000 Caen, France.
  • Department of Pathology, Caen University Hospital, F-14000 Caen, France.
  • Unicancer, Comprehensive Cancer Center F. Baclesse, Biological Ressources Centre OvaRessouces, F-14000 Caen, France.
  • Services Unit PLATON, Virtual'his Core Facility, Université de Caen Normandie, F-14000 Caen, France.
  • CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41-UAR 2014-PLBS, University of Lille, F-59000 Lille, France.

ORCID-Profile: Enora Dolivet, Christophe Denoyelle, Raffaèle Fauvet

Förderung

  • Ligue Contre le Cancer
  • Les Courants de la Liberté
  • Cancéropole Nord-Ouest
  • Les courants de la Liberté—La Rochambelle
  • Ligue contre le Cancer—Conférence de Normandie
  • Rose sur Green
  • Inserm, Université de Caen Normandie and Comprehensive Cancer Center F. Baclesse

Zitieren

APA

Dolivet, E., Gaichies, L., Jeanne, C., Bazille, C., Briand, M., Vernon, M., Giffard, F., Leprêtre, F., Poulain, L., Denoyelle, C., Vigneron, N., & Fauvet, R. (2023). Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242116016

Vancouver

Dolivet E, Gaichies L, Jeanne C, Bazille C, Briand M, Vernon M, et al. Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242116016

BibTeX
@article{Dolivet2023,
  author = {Dolivet, Enora and Gaichies, Léopold and Jeanne, Corinne and Bazille, Céline and Briand, Mélanie and Vernon, Mégane and Giffard, Florence and Leprêtre, Frédéric and Poulain, Laurent and Denoyelle, Christophe and Vigneron, Nicolas and Fauvet, Raffaèle},
  title = {Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242116016}
}
Kostenlos starten →